Cargando…
FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED
Disclosure: K. Foster: Employee; Self; Viridian Therapeutics Inc. B.A. Dickinson: Employee; Self; Viridian Therapeutics Inc. R.M. Summerfelt: Employee; Self; Viridian Therapeutics Inc. A. She: Employee; Self; Viridian Therapeutics Inc. V. Bedian: Employee; Self; Viridian Therapeutics Inc. B. Katz: E...
Autores principales: | Foster, Kelly, Dickinson, Brent A, Summerfelt, Rochelle M, She, Angela, Bedian, Vahe, Katz, Barrett |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554431/ http://dx.doi.org/10.1210/jendso/bvad114.1891 |
Ejemplares similares
-
FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
por: Douglas, Raymond, et al.
Publicado: (2023) -
OR26-02 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED), Binds To A Distinct Epitope From Teprotumumab
por: Bedian, Vahe, et al.
Publicado: (2023) -
Test de esperanza-desesperanza (TED TED-R) /
por: Pereyra Lavandina, Marío Ramón
Publicado: (2014) -
PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022) -
Ted Kennedy
por: David, Lester
Publicado: (1974)